AB
ABVX.O
—
NASDAQ
Biotechnology
Abvx.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
9,8B USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$124,33
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About
Abivax SA is a biotechnology company operating within the Health Care sector, though specific operational details and revenue sources are not disclosed in the available data.
Business. Abivax SA is a biotechnology company operating within the Health Care sector, though specific operational details and revenue sources are not disclosed in the available data.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
UBS Financial Services, Inc.
largest disclosed fund holder
Profitability
—
not yet wired
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ABVX.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Abivax SA is a biotechnology company operating within the Health Care sector, though specific operational details and revenue sources are not disclosed in the available data.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATED(a) Capital structure and liquidity cannot be assessed due to the absence of balance-sheet line items, cash-flow data, or debt metrics in the financial snapshot. The valuation snapshot indicates a market capitalization of $9.74 billion based on a share price of $124.00 and 78.54 million basic shares outstanding. No current ratio, debt-to-equity, or cash position is available to evaluate financial stability.
(b) Profitability and return metrics are entirely absent from the input data. There is no revenue, net income, EBITDA, ROE, or ROA data to compare against cohort medians or industry benchmarks. Consequently, the company’s economic engine and margin profile remain undefined in this analysis.
Key takeaways
- Market capitalization is $9.74 billion with 78.54 million shares outstanding.
- Dilution risk is assessed as low.
- Liquidity risk is unknown due to missing balance-sheet data.
- Classification confidence is low (0.20) despite Biotechnology industry tagging.
- No financial performance, growth, or segment data is available for analysis.
- Recent activity is limited to internal system reconciliation events.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$125,40
Market cap
$9.74B
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
—
Net cashⓘ
—
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
—
ROEⓘ
—
Cash conversionⓘ
—
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -3,21 |
| Revenue | —no estimate | —no estimate | 2,6M |
| Operating income | —no estimate | —no estimate | -248,7M |
Full-year consensus mean (period as reported by source). Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Corporate eventM&A horizon
M&A probabilityconf 3 %
Probability
3 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-18 · 1,0× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-07-22
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution12 analysts
Strong buy5
Buy6
Hold1
Sell0
Strong sell0
12-month price target$159,83 · Median $156,50
Low $140,00High $187,00
Operating income · consensus-248,7M
EPS surprise
−50,4 %
reported vs consensus · miss
Revenue surprise
+76,8 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskUnknown
Benchmarks vs cohort
No cohort benchmark data available for this issuer yet.
Corporate actions / M&A
M&A probabilityconf —
Probability
3 %
Base rate
3 %
Band
Low
180-day horizon · target 2027-01-18 · 1,0× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Abivax S.A. Market data — financials · 2026-08-02
- reconciler_enqueue (reconciler) on ABVX.O · 2026-08-02
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,09 %$506M
- Institutional Investor · as of 2026-03-310,05 %$98M
- Investment Managers · as of 2026-03-310,02 %$35M
- Investment Managers · as of 2026-03-310,02 %$23M
- Investment Managers · as of 2026-03-310,01 %$190M
- Investment Managers · as of 2026-03-310,01 %$43M
- Investment Managers · as of 2026-03-310,01 %$0M
- Institutional Investor · as of 2026-03-310,01 %$143M
- Investment Managers · as of 2026-03-310,01 %$39M
- Investment Managers · as of 2026-03-310,00 %$8M
- Funds · as of 2026-03-310,00 %$14M
- Institutional Investor · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
Insider activity
— missing data
Short positioning
4.0Mshares short-7.1% vs prior
2.36days to cover
50.8%short of daily vol
54.8Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ABVX.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskUnknown
Evidence & claims
From filings & derived data— missing data
The Thread
Everything we know, in order2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-23 03:11 UTCHOLDERInstitutional holding changed
2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-21 02:57 UTCHOLDERInstitutional holding changed
2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage